The General Hospital Corporation

Rhode Island Hospital, a Lifespan-partner

The Broad Institute, Inc.

Rhode Island Hospital

Massachusetts Institute of Technology

Temple University

Emory University

Brown University

Universidade Estadual Paulista/unesp

Eleftherios Mylonakis

Frederick M Ausubel

Wooseong Kim

Edward Holson

William Martin Wuest

Stephen B Calderwood

Helen Burgwyn Fuchs

Costi D Sifri

Jacqueline E Heard

Gary B Ruvkun

Laurence G Rahme

Georg Jander

Anita Shukla

Man-Wah Tan

Juliana Campos Junqueira

Raj Mohan Raja Muthiah

Beth Fuchs

Danielle A Garsin

Hanyang Liu

Andrew Diener

Julia Plotnikova

Nagendran Tharmalingam

The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by

Antibiotic compounds

The invention provides an auranofin-releasing antibacterial and antibiofilm polyurethane (PU) catheter coating. Auranofin is an antirheumatic drug with recently identified antimicrobial properties.

Auranofin-releasing antibacterial and antibiofilm polyurethane intravascular catheter coatings

The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by, methicillin-resistant(MRSA), vancomycin-resistant(VRSA),, and. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by, methicillin-resistant(MRSA), vancomycin-resistant(VRSA),. spp.,, and. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by, and

Antibacterial and antifungal compounds

The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Antibacterial compounds

The invention provides a method and bacterial compositions for reducing or preventing an infection of a bodily tissue by a fungal microorganism by contacting the tissue with a composition comprising a purifiedbacterium.

Probiotic bacteria-directed prevention or treatment of fungal infection

Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated within a subject infected by, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

[object Object]

Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Modified saponins for the treatment of fungal infections

The invention generally provides a novel approach to identifying Enterococcal virulence factors and for identifying compounds for treating bacterial pathogenesis. The invention further provides Enterococcal virulence factors, which serve as targets for drug discovery.

Photolyase nucleic acids

Screening procedures are disclosed for identifying compounds useful for inhibiting fungal infection or pathogenicity. Methods are also disclosed for identifying fungal pathogenic virulence factors.

Methods of screening compounds useful for prevention of infection or pathogenicity

Growing community of inventors

Providence, RI, United States of America

Eleftherios Mylonakis